Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin
- 760 Downloads
The addition of a single injection of insulin to the oral drugs (basal supported oral therapy; BOT) has been shown to greatly reduce blood glucose levels. The intermediate-acting NPH insulin (NPH) and the long-acting insulin glargine (Lantus®) have been compared for use in BOT in numerous clinical trials; however, their efficacy and safety in a real-life setting have not been described.
TIP (therapeutic benefits of patients on insulin glargine vs. NPH insulin being poorly controlled on prior short-time basal-insulin supported therapy with NPH insulin or insulin glargine) is a non-interventional, multicentre, observational study over 24 weeks. A total of 2629 patients were enrolled and 1931 were fully evaluable (1614 insulin glargine, 303 NPH insulin). Propensity scoring (PSM) was used to match 570 patients into 2 similar cohorts of 285 patients.
In the PSM cohort, a slightly greater reduction in FBG and HbA1c levels was seen in the insulin glargine group compared to the NPH group. A weight loss, which was slightly more pronounced in insulin glargine patients despite receiving a lower insulin dose relative to the NPH group, was seen in both the groups. Additionally, hypoglycaemia, including nocturnal and severe events, was more prevalent in the patients receiving BOT with NPH. The occurrence of new micro- or macro-vascular complications and adverse events was low for both groups. A large proportion of patients changed from NPH therapy to insulin glargine therapy during the study, which was mainly attributable to insufficient glucose modulation. Improvements in quality of life and treatment satisfaction were found for both types of insulin.
This observational study provides evidence from a real-life setting that BOT with insulin glargine provides slightly greater reductions in weight, FBG and HbA1c levels, with a lower risk of hypoglycaemia than patients receiving NPH. This conclusion indicates that insulin glargine may be preferable to NPH insulin for BOT.
KeywordsBasal supported oral therapy Insulin Glargine Lantus® NPH Isophane
The analysis was funded by Sanofi, Berlin, Germany.
HF designed the study. TW, AF, HF, and PB were involved in the analysis and interpretation of the data. PB drafted the first version of the manuscript, and all authors revised the article for important intellectual content. The final version was approved by all authors.
Compliance with ethical standards
Conflict of interest
TW and AF have attended advisory boards and received compensation from Sanofi Aventis Deutschland GmbH, Berlin, Germany. HF is an employee of Sanofi, Berlin, Germany. PB has received research funding and honoraria for consultancy from AstraZeneca, Bristol-Myers Squibb, Novartis, and Sanofi.
The procedures in this study were in accordance with the ethical standards of the Declaration of Helsinki. The study protocol was approved by the ethics committee of the Berlin Chamber of Physicians. Furthermore the study was performed in accordance with the protocol, applicable local regulations and international guidelines.
Human and animal rights
All human rights were observed in keeping with the Declaration of Helsinki. There are no animal rights issues.
Written informed consent was obtained from all patients for being included in the study which has been done according to ethical standards and in keeping with the Declaration of Helsinki.
- 2.American Diabetes, A (2016) 7. Approaches to glycemic treatment. Diabetes Care 39(Suppl 1):S52–S59Google Scholar
- 6.Rys P et al (2015) Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 52(4):649–662CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Mullins P et al (2007) Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 29(8):1607–1619CrossRefPubMedGoogle Scholar
- 35.Korytkowski M et al (2003) A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 25(11):2836–2848CrossRefPubMedGoogle Scholar